Data Sheet 1_The potential of olfaction loss to induce cognitive impairment and anxiety behavior in mice via the microbiota-gut-brain axis.pdf by Xiangyu Zhao (1497469)

“…</p>Results<p>Olfactory loss not only causes a significant decrease in food intake and body weight and an increase in O₂ consumption but also induces cognitive impairment and anxiety behavior. …”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Table 1_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.docx by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Image 3_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.png by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Table 4_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.xlsx by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Table 3_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.xlsx by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Image 2_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.png by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Table 2_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.xlsx by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Image 1_The activity of cell-free supernatant of Lactobacillus crispatus M247: a promising treatment against vaginal infections.png by Giulia Santarelli (14246638)

“…We observed a slight decrease in the microbial burden following LcM247 administration, while treatment with CFS significantly reduced microbial growth compared to control and antimicrobial compounds. …”

Data Sheet 1_Exploring the role of neutrophils in inflammatory pain hypersensitivity via single-cell transcriptome profiling.pdf by Kai Ding (783198)

“…</p>Results<p>scRNA-seq revealed a significant increase in neutrophils and a decrease in monocytes among CD11b⁺ cells following surgery and CFA treatment. …”

Data Sheet 3_Exploring the role of neutrophils in inflammatory pain hypersensitivity via single-cell transcriptome profiling.pdf by Kai Ding (783198)

“…</p>Results<p>scRNA-seq revealed a significant increase in neutrophils and a decrease in monocytes among CD11b⁺ cells following surgery and CFA treatment. …”

Data Sheet 2_Exploring the role of neutrophils in inflammatory pain hypersensitivity via single-cell transcriptome profiling.xlsx by Kai Ding (783198)

“…</p>Results<p>scRNA-seq revealed a significant increase in neutrophils and a decrease in monocytes among CD11b⁺ cells following surgery and CFA treatment. …”

Data Sheet 1_Antifungal activity of cinnamaldehyde against Aspergillus fumigatus involves disruption of the TCA cycle and protein metabolism.pdf by Fang Li (41162)

“…Following treatment with CA, the protein expression of the putative translation initiation factor eIF4E3 (AFUB_051690), the putative leucyl-tRNA synthetase LeuRS (AFUB_093380), prolyl-tRNA synthetase ProRS (AFUB_010170) and the putative peptidyl-tRNA hydrolase Pth1 (AFUB_053480) exhibited a significant decrease. Moreover, deletion of pth1 resulted in a severe growth defect and hypersensitivity to CA, as evidenced by complete growth arrest at 30 and 45 μg/mL CA. …”

Table 1_Antifungal activity of cinnamaldehyde against Aspergillus fumigatus involves disruption of the TCA cycle and protein metabolism.docx by Fang Li (41162)

“…Following treatment with CA, the protein expression of the putative translation initiation factor eIF4E3 (AFUB_051690), the putative leucyl-tRNA synthetase LeuRS (AFUB_093380), prolyl-tRNA synthetase ProRS (AFUB_010170) and the putative peptidyl-tRNA hydrolase Pth1 (AFUB_053480) exhibited a significant decrease. Moreover, deletion of pth1 resulted in a severe growth defect and hypersensitivity to CA, as evidenced by complete growth arrest at 30 and 45 μg/mL CA. …”

Image 1_Antifungal activity of cinnamaldehyde against Aspergillus fumigatus involves disruption of the TCA cycle and protein metabolism.tif by Fang Li (41162)

“…Following treatment with CA, the protein expression of the putative translation initiation factor eIF4E3 (AFUB_051690), the putative leucyl-tRNA synthetase LeuRS (AFUB_093380), prolyl-tRNA synthetase ProRS (AFUB_010170) and the putative peptidyl-tRNA hydrolase Pth1 (AFUB_053480) exhibited a significant decrease. Moreover, deletion of pth1 resulted in a severe growth defect and hypersensitivity to CA, as evidenced by complete growth arrest at 30 and 45 μg/mL CA. …”

Data Sheet 2_Antifungal activity of cinnamaldehyde against Aspergillus fumigatus involves disruption of the TCA cycle and protein metabolism.pdf by Fang Li (41162)

“…Following treatment with CA, the protein expression of the putative translation initiation factor eIF4E3 (AFUB_051690), the putative leucyl-tRNA synthetase LeuRS (AFUB_093380), prolyl-tRNA synthetase ProRS (AFUB_010170) and the putative peptidyl-tRNA hydrolase Pth1 (AFUB_053480) exhibited a significant decrease. Moreover, deletion of pth1 resulted in a severe growth defect and hypersensitivity to CA, as evidenced by complete growth arrest at 30 and 45 μg/mL CA. …”